The Enforcement Nexus: DOJ's Expanding Reach, FDA's Dual Focus on Access & Safety, and CMS's PBM Probe

2026-06-19

Healthcare compliance is not a static endeavor. This week's regulatory landscape reveals a dynamic interplay of heightened federal scrutiny, evolving pharmaceutical access, and deep dives into industry practices, demanding proactive vigilance from every healthcare operator. From robust anti-kickback enforcement to critical OTC drug updates, the message is clear: compliance is comprehensive.

The drumbeat of healthcare compliance continues to grow louder, underscored by a flurry of regulatory actions and inquiries that signal an increasingly complex operational environment. For telehealth innovators, multi-state practice owners, and healthcare investors, understanding these shifts isn't just about avoiding penalties; it's about safeguarding business models and ensuring sustainable growth. This week, we dissect critical developments from the Department of Justice (DOJ), the Food and Drug Administration (FDA), and the Centers for Medicare & Medicaid Services (CMS), revealing a landscape where enforcement is broad, patient safety is paramount, and transparency is becoming non-negotiable.

> For more on this topic, see our analysis: [Navigating the New Enforcement Landscape: A Mid-Year Compliance Briefing for Healthcare Executives](/blog/healthcare-compliance-digest-enforcement-trends-q2-2024).

Broadening the Anti-Kickback Scope: DOJ's Unwavering Commitment to Procurement Integrity

Recent federal enforcement actions send a clear, albeit indirect, message to the healthcare sector: the government's commitment to combating fraud and kickbacks extends far beyond traditional healthcare billing schemes. The Department of Justice's Procurement Collusion Strike Force (PCSF) recently secured a guilty plea from David Duggin, a former U.S. Intelligence Community contractor, for conspiring to commit offenses against the United States by soliciting and accepting over $510,000 in illegal kickbacks. While this case did not directly involve healthcare, its implications for our industry are profound and undeniable.

The PCSF's mandate explicitly targets schemes impacting "government procurement, grant and program funding at all levels of government — federal, state and local." This broad scope means that any healthcare entity that participates in federal or state programs, receives government grants, or contracts with government agencies (which includes virtually all practices that accept Medicare or Medicaid) falls squarely within the PCSF's potential purview. The underlying principles of the Anti-Kickback Statute (AKS) and the False Claims Act (FCA) are fundamentally about preventing illegal inducements that distort medical decision-making or corrupt government-funded processes. The Duggin case reinforces the DOJ's aggressive posture against any form of financial impropriety that undermines fair competition or honest dealings with the government.

For healthcare practices, this means:

Enhanced Scrutiny of All Government Funding: Whether it's direct reimbursements, grants for specific initiatives, or contracts for services provided to government employees, any financial arrangement involving public funds requires meticulous compliance.
Diligent Review of Vendor Relationships: Practices must ensure that all agreements with third-party vendors, suppliers, and referral sources are transparent, commercially reasonable, and free from any direct or indirect inducements that could be construed as kickbacks. This includes arrangements for electronic health record (EHR) systems, lab services, consulting, or marketing.
Robust Compliance Programs: A strong, continuously updated compliance program is your best defense. This includes regular training, internal audits, and a clear reporting mechanism for potential violations. Ignorance is not a defense, and the penalties for AKS and FCA violations can be catastrophic, including significant fines, exclusion from federal programs, and even criminal charges.

FDA's Dual Mandate: Expanding Access and Bolstering Safety Warnings

The FDA's actions this week highlight its complex role in both facilitating access to critical medications and ensuring patient safety. These developments have direct implications for how healthcare providers counsel patients and manage their clinical workflows.

Expanding Opioid Overdose Access with OTC Naloxone

The approval of Rextovy, a 4 mg naloxone hydrochloride nasal spray, for over-the-counter (OTC) sale marks a significant step in the federal government's efforts to combat the opioid crisis. This follows the earlier OTC approval of Narcan and further democratizes access to a life-saving medication for emergency opioid overdose treatment. For telehealth brands, dental practices, chiropractic offices, and medspas, this isn't just a public health announcement; it's a call to action for patient education.

While prescribers are not directly involved in the OTC sale, every healthcare provider has a role in discussing naloxone availability and proper use. This is particularly relevant for:

Patients on Opioid Therapy: Dental and chiropractic patients prescribed opioids for acute pain should be educated on the risks and the immediate availability of OTC naloxone for their households.
Wellness and Prevention Programs: Telehealth platforms and wellness clinics should integrate information about naloxone into broader health discussions, especially for patients or their family members at elevated risk of opioid use disorder.
Community Engagement: Healthcare businesses can position themselves as community health leaders by actively disseminating information about OTC naloxone, empowering individuals to respond effectively to emergencies.

Heightened Scrutiny for OTC Weight Loss Drugs: The Alli Label Update

In a move demonstrating continued regulatory vigilance over even widely available OTC products, the FDA has mandated crucial updates to the 'Drugs Facts Label' for alli (orlistat) 60 mg capsules. The revised labeling now includes explicit warnings about rare but serious risks of acute kidney injury, kidney stones, and other kidney-related issues. This action aligns alli's labeling with the higher-strength prescription version, Xenical, ensuring consistent safety information.

This update underscores several critical points for healthcare providers:

Comprehensive Patient Intake: It reinforces the absolute necessity of thoroughly reviewing all medications and supplements a patient is taking, including OTC products. Patients often don't consider OTC drugs to be significant when listing their medications, yet they can carry serious risks and interact with other conditions or prescriptions.
Patient Counseling on OTC Use: Providers across all specialties, particularly those in medspas or wellness practices offering weight management services, must be prepared to counsel patients on the potential risks of OTC weight loss aids like alli. Proactively inquiring about their use and advising on when to seek medical attention for adverse symptoms (e.g., signs of kidney injury) is crucial.
Holistic Risk Assessment: When discussing weight management strategies, practitioners must consider a patient's full health profile, including a history of kidney disease or stones, and advise accordingly regarding OTC options.

Supply Chain Integrity: FDA's Debarment Enforcement

Further emphasizing its role in safeguarding the pharmaceutical supply chain, the FDA issued a final debarment order against Andrew Jonathan Morgan for a felony conviction related to drug importation. This 5-year debarment prohibits him from importing or offering for import any drug into the U.S. This enforcement action is a stark reminder for all healthcare businesses of the critical importance of robust due diligence in sourcing medical products.

Practices must rigorously vet all suppliers of drugs, controlled substances, and even medical devices. Unknowingly procuring products from debarred individuals or entities can lead to severe compliance risks, supply chain disruptions, and significant legal liabilities. Verifying the legitimacy and regulatory standing of your supply chain partners is not merely a best practice; it is a fundamental requirement for maintaining patient safety and operational integrity.

CMS Sets the Stage for PBM Transparency: A Long-Term Shift

The Centers for Medicare & Medicaid Services (CMS) has initiated a Request for Information (RFI) to gather technical input on the services and business practices of Pharmacy Benefit Managers (PBMs). This RFI is a foundational step towards implementing recent legislation concerning PBM remuneration restrictions and data reporting requirements, both slated to take effect in Calendar Year 2028.

While 2028 seems distant, this RFI signals a clear, long-term trajectory toward greater transparency and accountability within the PBM sector. For healthcare providers, particularly those involved in prescribing medications or managing patient drug benefits under Medicare Part D, these potential changes could have profound ripple effects:

Impact on Drug Costs and Formularies: Increased transparency and revised PBM compensation models could influence medication costs, which drugs are covered on formularies, and patient out-of-pocket expenses. This directly impacts patient adherence and the financial feasibility of prescribed treatments.
Provider Reimbursement: Changes in the PBM landscape could indirectly affect reimbursement for drug-related services, especially for practices that dispense medications in-office or manage complex drug regimens.
Patient Access to Medications: Alterations in PBM practices might shift pharmacy networks or influence the availability of certain drugs, requiring providers to stay informed to guide patients effectively.
Corporate Practice of Medicine (CPOM) Considerations: Practices operating in states with strict CPOM regulations, or those considering dispensing activities, should closely monitor how evolving PBM regulations intersect with state-level restrictions on who can own or operate pharmacies and control drug supply chains.

This RFI is a preliminary step, but it marks the beginning of a significant shift. Healthcare businesses should view this as an early warning to begin evaluating their current medication management protocols, understanding their patient's benefit structures, and anticipating potential changes in the pharmaceutical landscape that could affect clinical decisions and business operations.

What This Means For Your Practice

The regulatory developments of this week paint a vivid picture of a healthcare environment demanding proactive, comprehensive compliance. For telehealth founders, brick-and-mortar practice owners expanding nationally, healthcare compliance officers, medspa and specialized practice owners, and healthcare investors, several actionable insights emerge:

1. Elevate Your Anti-Kickback Vigilance: Do not confine your anti-kickback compliance to just traditional referral sources. Extend your scrutiny to *all* financial arrangements involving government funds, contracts, or procurement. Review vendor agreements, marketing partnerships, and any compensation structures for potential red flags. The DOJ's reach is broad, and its enforcement against fraud is relentless. 2. Become a Resource for OTC Drug Safety and Access: Healthcare providers are increasingly on the front lines of public health beyond prescription pads. Integrate patient education on OTC naloxone availability into your patient counseling, particularly for those at risk or with family members at risk of opioid overdose. Similarly, rigorously question patients about all OTC medications, especially weight loss aids, and be prepared to advise on their risks and interactions. Your role in patient safety extends to the entire medication cabinet. 3. Fortify Your Supply Chain Due Diligence: The FDA debarment serves as a critical reminder that your supply chain is only as strong as its weakest link. Implement rigorous vetting processes for *all* suppliers of medical products, drugs, and controlled substances. Verify their regulatory standing, licensure, and ensure they are not debarred or facing other enforcement actions. Patient safety and operational continuity depend on a pristine supply chain. 4. Prepare for a More Transparent Pharmaceutical Future: While PBM changes are years away, the CMS RFI signals an inevitable shift towards greater transparency in drug pricing and benefit management. Start to understand how PBMs impact your patients' access and costs today. Anticipate future implications for your practice's prescribing patterns, patient education, and potentially even your revenue cycle if drug costs and reimbursements shift. Strategic foresight in this area can provide a significant competitive advantage.

The regulatory current is strong and dynamic. TrueEval provides the intelligence and infrastructure to navigate these waters with confidence, transforming compliance from a burden into a strategic asset. Proactive engagement with these evolving requirements is not just good practice; it's essential for sustained success in modern healthcare.